Summary of patients and LGD samples used as the validation data by progression status, clinical features and endoscopic findings
| Data type | Variable | Progressor LGD | Non-progressor LGD | Significance between groups |
| Cases | Number of patients | 18 | 37 | N/A |
| Number of lesions | 22 | 37 | ||
| Number of regions | 43 | 63 | ||
| Clinical features | Days to censor | 729 days IQR 221–1450 | 2726 days IQR 1828–3401 | N/A |
| Gender (% male) | 72% | 76% | NS* (p=0.32) | |
| Median age (years) | 60 (range 32–82) | 62 (range 28–76) | NS† (p=0.99) | |
| Median duration of disease (years) | 22 (range 4–33; n=14) | 13 (range 1–64; n=31) | NS† (p=0.06) | |
| Proportion with PSC | 16.7% | 13.5% | NS* (p=1) | |
| Lesion features | Lesion spatial distribution | 90% left colorectum 10% right colon n=21 | 58% left colorectum 42% right colon n=36 | Significant* (p=0.02) |
| Lesion morphology | 33% polypoid 22% non-polypoid 44% invisible n=18 | 83% polypoid 8% non-polypoid 8% invisible n=36 | Significant‡ (p=0.001) | |
| Median size of visible lesions (mm) | 45 (range 5–50) n=5 | 9 (range 2–150) n=25 | Significant† (p=0.04) |
*Fisher’s exact test.
†Mann-Whitney test.
‡χ2 test of independence.
LGD, low-grade dysplasia; N/A, not available; NS, not significant; PSC, primary sclerosing cholangitis.